Skip to NavigationSkip to content

Novoheart

AstraZeneca and Novoheart team up to develop human ‘heart-in-a-jar’

AstraZeneca and Novoheart are collaborating on developing a functioning miniature human heart model of heart failure, a first of its kind.

The ‘heart-in-a-jar’, Novoheart’s proprietary 3D human ventricular cardiac organoid chamber (hvCOC) technology, will be made from human stem cells and will replicate the key characteristics of heart failure. This will include preserved ejection fraction (HFpEF), a common condition especially in women and the elderly.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches